Ipilimumab, Nivolumab, and Brentuximab Vedotin Combination Therapies in Relapsed/Refractory HL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ipilimumab, Nivolumab, and Brentuximab Vedotin Combination Therapies in Patients With Relapsed or Refractory Hodgkin Lymphoma: Phase 1 Results of an Open-Label, Multicentre, Phase 1/2 Trial
Lancet Haematol 2020 Sep 01;7(9)e660-e670, CS Diefenbach, F Hong, RF Ambinder, JB Cohen, MJ Robertson, KA David, RH Advani, TS Fenske, SK Barta, ND Palmisiano, J Svoboda, DS Morgan, R Karmali, E Sharon, H Streicher, BS Kahl, SM AnsellFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.